PneumaCult™ Apical-Out Airway Organoid Medium

Serum- and BPE-free medium for differentiation of human primary bronchial epithelial cells or human airway epithelial cells to mature apical-out airway organoids

Interested in trying STEMCELL's organoid products for respiratory research? Fill out this form to request information about introductory offers.

PneumaCult™ Apical-Out Airway Organoid Medium

Serum- and BPE-free medium for differentiation of human primary bronchial epithelial cells or human airway epithelial cells to mature apical-out airway organoids

Catalog #
(Select a product)
Serum- and BPE-free medium for differentiation of human primary bronchial epithelial cells or human airway epithelial cells to mature apical-out airway organoids
Request Pricing

Product Advantages


  • Convenient, in vitro system that provides easy access to the apical side of the airway epithelium

  • Easy downstream processing with a Matrigel®-free protocol

  • Generates homogeneous organoids across donors

  • Suitable for high-throughput drug screening applications

What's Included

  • PneumaCult™ Apical-Out Airway Organoid Medium, Catalog #100-0620
    • PneumaCult™ Apical-Out Airway Organoid Basal Medium, 450 mL
    • PneumaCult™ Apical-Out Airway Organoid 10X Supplement, 50 mL
    • PneumaCult™ Apical-Out Airway Organoid 1000X Supplement, 500 µL
Products for Your Protocol
To see all required products for your protocol, please consult the Protocols and Documentation.

Overview

Generate apical-out airway organoids in 15 days from human bronchial epithelial cells (HBECs) or human airway epithelial cells (HAECs) with a simple and scalable, Matrigel®-free protocol. These organoids provide access to the apical side of the airway epithelium and can be used to perform your infectious disease modeling or high-throughput drug screening in an in vitro, three-dimensional (3D) model system.

With PneumaCult™ Apical-Out Airway Organoid Medium, you can grow polarized airway organoids with outward-facing, differentiated ciliated cells in AggreWell™400 24-well plates (Catalog #34415)—without the use of cell culture inserts. To maximize experimental reproducibility, this medium is formulated without serum or BPE. For a complete apical-out airway organoid culture workflow, expand your HBECs or HAECs in PneumaCult™-Ex Plus Medium (Catalog #05040) prior to initiating organoid culture with PneumaCult™ Apical-Out Airway Organoid Medium.

Find more about the applications of lung organoids in our learning center.
Subtype
Specialized Media
Cell Type
Airway Cells, Epithelial Cells
Species
Human
Application
Cell Culture, Differentiation, Organoid Culture
Brand
PneumaCult
Area of Interest
Disease Modeling, Drug Discovery and Toxicity Testing, Epithelial Cell Biology, Infectious Diseases, Organoids, Respiratory Research, Stem Cell Biology
Formulation Category
Serum-Free

Data Figures

Generation of Apical-Out Airway Organoids Using the PneumaCult™ Apical-Out Airway Organoid Medium

Figure 1. Generation of Apical-Out Airway Organoids Using the PneumaCult™ Apical-Out Airway Organoid Medium

(A) Workflow showing the generation of apical-out airway organoids. (B) Prior to generating apical-out airway organoids, human airway epithelial cells (HAECs) are expanded using PneumaCult™-Ex Plus medium in a two-dimensional expansion phase. (C)The HAECs are then plated into an AggreWell™400 24-well plate and allowed to aggregate for 1 - 6 days using PneumaCult™ Apical-Out Airway Organoid medium. (D) Following aggregation, the cells are dislodged from the microwells and the aggregate suspension is transferred to a 24-well flat-bottom plate and differentiated for 9 - 14 days using PneumaCult™ Apical-Out Airway Organoid medium to generate apical-out airway organoids. (E) The resulting organoids are composed of a cell-dense core containing basal cells and an epithelium that presents ciliated cells on the outer surface, indicating their successful apical-out polarity. Shown are representative brightfield images at different stages of the workflow.

Figure 2. PneumaCult™ Apical-Out Airway Organoid Medium Supports Efficient Generation of Organoids

Apical-out airway organoids were generated by seeding 100 2D-expanded cells derived from 3 donors from passages 3 to 8. (A) Number of generated organoids per well of a 24-well plate at day 15. Data points represent measurements taken from independent wells of a 24-well plate. (B) The efficiency of two different approaches (ECM-free PneumaCult™ Apical-Out Airway Organoid medium workflow or polarity inversion following ECM removal) is expressed as the percentage of apical-out airway organoids at the end of culture relative to the total number of organoids used to seed the cultures.

Figure 3. PneumaCult™ Apical-Out Airway Organoid Medium Supports Standardized Generation of Organoids

Absence of extracellular matrix, and aggregation using AggreWell™400 24-well plate, allows for homogeneity of the culture and the standardized generation of apical-out airway organoids that are highly similar in shape and size. For each donor at passage 3, 750 organoids were counted from 3 separate wells to generate a (A) histogram depicting the frequency of diameters in apical-out airway organoids. Organoid diameter is consistent between all donors, supporting the homogeneity of the culture. To quantify the number of cells that the organoids were composed of, passage 3 organoids were fixed, stained with DAPI, and imaged to visualize the number of nuclei and determine the (B) number of cells comprising each organoid. On average, organoids were composed of 62 cells with a 95% confidence interval of 6.77, demonstrating homogeneity at the cellular level. (C) Ciliated cell percentage of apical out organoids at day 15, (D) and the percentage of motile organoids that display beating cilia. Almost all organoids displayed functional beating cilia that allowed them to move in suspension after multiple passages, further demonstrating the homogeneity of the culture.

Figure 4. Apical-Out Airway Organoid Production Can Be Scaled-Up

Human airway epithelial cells (HAECs) were seeded at the same density in both the 6-well and 24-well AggreWell™ 400 plates with PneumaCult™ Apical-Out Airway Organoid medium. Data points represent individual wells analyzed on day 15 of passage number 5 for each. (A) The number of organoids obtained per well in an AggreWell™400 6-well plate was, on average, three times higher than in the 24-well plate format. (B) These organoids demonstrated similar differentiation potential and proportion of ciliated cells when compared to the 24-well format. (C) These organoids also displayed a high degree of size homogeneity between the two AggreWell™400 formats tested. This suggests that production can be scaled up without compromising the quality and functionality of the airway organoids.

Figure 5. Gene Expression Analysis of Organoids Cultured in PneumaCult™ Apical-Out Airway Organoid Medium Shows Presence of Various Airway Cell Types

Heatmap showing fold changes in the RNA levels of common differentiation markers in apical-out airway organoids cultured in PneumaCult™ Apical-Out Airway Organoid Medium across 2 different passages, in three donors. Results were normalized against HBECs cultured in PneumaCult™-Ex Plus Medium and analyzed at passage three (n = 3). Ciliated cell markers, FOXJ1 and TUBB4B are upregulated in terminally differentiated apical-out airway organoids compared to ALI cultures. Additionally, the presence of ACE2 and TMPRSS2 markers suggests that organoids cultured in PneumaCult™ Apical-Out Airway Organoid Medium are a suitable in vitro tool to model respiratory infection by viruses such as SARS-CoV-2.

Figure 6. Terminally Differentiated Organoids Exhibit Mature Polarized Airway Epithelium

(A) Day 15 apical-out airway organoids cultured in PneumaCult™ Apical-Out Airway Organoid Medium contain ciliated cells, as confirmed by the presence of acetylated tubulin (AC. TUB; green) on the outward-facing apical cell surface, while keratin 5 (KRT5; red)-expressing basal cells were present alongside ciliated cells. (B) Cell-cell tight junction protein ZO-1 (red) can be readily visualized on the apical side of the organoid. These results indicate efficient generation of organoids across multiple passages with successful apical-out orientation. (C) Presence of ciliated cell marker acetylated tubulin (AC.TUB; yellow) and SARS-CoV-2 key entry marker ACE2 (red) is also shown, suggesting their usefulness for modeling respiratory infection from SARS-CoV-2.

Figure 7. Apical-Out Airway Organoids Are Susceptible to Infection with Influenza A, Influenza B, and Rhinovirus A-16

(A) Terminally differentiated apical-out airway organoids were infected with Influenza A (IAV), Influenza B (IBV), and Rhinovirus-A16 (RV-A16). The viral loads in the supernatant were detected by qPCR in samples harvested at 24-hour intervals. Data points represent mean values of all biological replicates (n = 3) and error bars represent the standard deviation. When compared to (B) mock-infected organoids, the infected apical-out airway organoids showed clear signs of cytopathogenic effect (CPE) following infection with (C) RV-A16, (D) IAV, and (E) IBV 48 hours post infection. Differences in the pathogenicity of each virus could be detected; high levels of CPE were observed in apical-out airway organoids infected with IAV or IBV, whereas apical-out airway organoids infected with RV-A16 showed only moderate levels of CPE.

Figure 8. Mature Organoids Were Incubated with Enterovirus-D68 in the Presence or Absence of Itraconazole (ITZ) or Rupintrivir (RUP) to Study Antiviral Effects

To assess whether the PneumaCult™ Apical-Out Airway Organoid system was susceptible to infection to common respiratory viruses, day 15 differentiated organoids were infected with enterovirus-D68 (EV-D68). (A) At 0 hours post infection, the EV-D68 (VP1, green) could be seen binding to the apical surface (ciliated cells; acetylated tubulin; red). (B) After 6 hours, cells containing double-strand RNA (dsRNA; red), an intermediate stage during the viral replication cycle, can be identified. These cells are also positive for viral protein (VP1, green) and (C and D, orange bars) generate high viral RNA titers, (E) while showing evidence of cytopathogenic effect (CPE). (C, teal bars) Treatment with Itraconazole (ITZ) reduced the viral RNA levels by approximately 2 orders of magnitude and (F) slightly ameliorated the CPE levels. (D, teal bars) Treatment with Rupintrivir (RUP) completely inhibited viral replication, (G) resulting in the absence of any CPE. (H) Measuring the Relative Fluorescent Units (RFU) 72 hours post infection indicated changes in the levels of ATP and viability of the organoids, and revealed a sharp decline in viability following infection with EV-D68. A partial rescue was detected in infected apical-out airway organoids treated with ITZ, whereas those treated with RUP were almost completely rescued.

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
100-0620
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
100-0620
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
100-0620
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
100-0620
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Interested in trying STEMCELL's organoid products for respiratory research? Fill out this form to request information about introductory offers.